Skip to main content
Terug
CRVS logo

Corvus Pharmaceuticals, Inc.

Datakwaliteit: 100%
Oversold
CRVS
NASDAQ Healthcare Biotechnology
€ 13,15
▼ € 0,60 (-4,36%)
Marktkapitalisatie: 1,10B
Dagbereik
€ 12,99 € 13,82
52-Weeksbereik
€ 2,54 € 26,95
Volume
1.179.540
50D / 200D Gem.
€ 16,97 / € 8,91
Vorige Slotkoers
€ 13,75

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (627 peers)

Metriek Aandeel Sector Mediaan
P/E -72,3 0,3
P/B 18,1 2,9
ROE % -32,6 3,7
Net Margin % 3,8
Rev Growth 5Y % 10,0
D/E 0,0 0,2

Koersdoel Analisten

Hold
€ 31,80 +141.8%
Low: € 27,00 High: € 42,00
Forward WPA
-€ 0,69
Omzet Sch.
1,2 M

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2030 € 0,12
€ 0,10 – € 0,14
240 M 2
FY2029 -€ 0,46
-€ 0,53 – -€ 0,38
130 M 4
FY2028 -€ 0,64
-€ 1,56 – € 0,05
58 M 6

Belangrijkste Punten

Debt/Equity of 0,02 — conservative balance sheet
Negative free cash flow of -32,97M
PEG of 0,49 suggests growth is underpriced

Groei

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-32,60%
ROIC-51,86%
Net MarginN/A
Op. MarginN/A

Veiligheid

Debt / Equity
0,02
Current Ratio6,21
Interest Coverage0,00

Waardering

P/E Ratio
-72,27
P/B Ratio18,05
EV/EBITDAN/A
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 0,0 Net Income (TTM) -15,28M
ROE -32,60% ROA -21,49%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -32,97M
ROIC -51,86% FCF Growth (3Y) N/A
Safety
Debt / Equity 0,02 Current Ratio 6,21
Interest Coverage 0,00 Dividend Yield 0,00%
Valuation
P/E Ratio -72,27 P/B Ratio 18,05
P/S Ratio N/A PEG Ratio 0,49
EV/EBITDA N/A Dividend Yield 0,00%
Market Cap 1,10B Enterprise Value 1,10B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 0,0 0,0 0,0 0,0 0,0
Net Income -15,28M -62,29M -27,03M -41,31M -43,24M
EPS (Diluted) -0,53 -1,02 -0,56 -0,89 -1,03
Gross Profit -105.000,0 0,0 0,0 0,0 0,0
Operating Income -42,97M -27,55M -23,41M -32,57M -38,63M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 71,12M 68,91M 45,55M 68,24M 109,46M
Total Liabilities 9,91M 36,34M 6,87M 12,13M 12,29M
Shareholders' Equity 61,21M 32,57M 38,68M 56,12M 97,16M
Total Debt 937.000,0 1,12M 1,37M 2,60M 3,65M
Cash & Equivalents 4,58M 8,74M 12,62M 13,16M 63,46M
Current Assets 58,21M 54,41M 27,96M 43,66M 71,31M
Current Liabilities 9,38M 35,40M 6,87M 10,75M 9,69M